{
    "root": "c11ff279-c752-44b6-bf85-a7c86670fd4c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mirtazapine",
    "value": "20240716",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "MIRTAZAPINE",
            "code": "A051Q2099Q"
        }
    ],
    "indications": "mirtazapine tablets indicated treatment major depressive disorder ( mdd ) adults [ ( 14 ) ] .",
    "contraindications": "• starting dose : 15-mg daily ; may increase maximum recommended dose 45 mg daily . ( 2.1 ) • administer orally daily , preferably evening prior sleep . ( 2.1 ) • reduce dose gradually discontinuing mirtazapine tablets . ( 2.6 , 5.14 )",
    "warningsAndPrecautions": "mirtazapine tablets , usp supplied : 30 mg - reddish-brown , oval , biconvex tablet - film coated tablets “ 500 ” debossed one side scored side . ndc 72162-1640-02 bottle 45 tablets ndc 72162-1640-03 bottle 30 tablets ndc 72162-1640-05 bottle 500 tablets ndc 72162-1640-00 bottle 1000 tablets storage store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) . [ usp controlled room temperature ] . protect light moisture . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "mirtazapine tablets contraindicated patients : •taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.3 ) , ( 7 ) ] . •with known hypersensitivity mirtazapine excipients mirtazapine tablets . severe skin , including reaction eosinophilia systemic symptoms ( dress ) , stevens-johnson syndrome , bullous dermatitis , erythema multiforme toxic epidermal necrolysis reported following mirtazapine tablets [ ( 5.6 ) , ( 6.2 ) ] .",
    "indications_original": "Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults \n                        [see Clinical Studies (14)].",
    "contraindications_original": "• Starting dose: 15-mg once daily; may increase up to maximum recommended dose of 45 mg once daily. (2.1) • Administer orally once daily, preferably in the evening prior to sleep. (2.1) • Reduce dose gradually when discontinuing mirtazapine tablets. ( 2.6 , 5.14 )",
    "warningsAndPrecautions_original": "Mirtazapine tablets, USP are supplied as:\n                  30 mg - Reddish-brown, oval, biconvex tablet - film coated tablets with “500” debossed on one side and scored on the other side.\n                  NDC 72162-1640-02 Bottle of 45 tablets\n                  NDC 72162-1640-03 Bottle of 30 tablets\n                  NDC 72162-1640-05 Bottle of 500 tablets \n                  NDC 72162-1640-00 Bottle of 1000 tablets\n                  \n                     \n                        Storage\n                     \n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted 15° to 30°C (59° to 86°F). [see USP Controlled Room Temperature]. Protect from light and moisture.\n                  Repackaged/Relabeled by:\n                  Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Mirtazapine tablets are contraindicated in patients: \n                  \n                     \n                        •Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome \n                           [see Warnings and Precautions (5.3), Drug Interactions (7)].\n                        \n                     \n                     \n                        •With a known hypersensitivity to mirtazapine or to any of the excipients in mirtazapine tablets. Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme and toxic epidermal necrolysis have been reported following the use of mirtazapine tablets \n                           [see Warnings and Precautions (5.6), Adverse Reactions (6.2)]."
}